Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Propanc Biopharma, Inc. (PPCB)

Propanc Biopharma: Director Annie Van Broekhoven resigns; Carlo Campiciano appointed to Board

Neutral Impact 2 of 5 leadership Written later

Effective July 8, 2026, Annie Van Broekhoven retired and stepped down from Propanc Biopharma's Board of Directors, and the Board appointed Carlo Campiciano to fill the vacancy. The filing describes Mr. Campiciano as a qualified accountant with prior experience as CFO and Company Secretary of MedAdvisor Limited, an ASX-listed company. The change is a board composition update and the filing does not report any financial results.

Key points

  • Annie Van Broekhoven retired and resigned from the Board effective July 8, 2026
  • Carlo Campiciano appointed to the Board the same day to serve until resignation or removal
  • Mr. Campiciano was CFO and Company Secretary of MedAdvisor Limited, an ASX-listed company
  • Director Agreement dated July 8, 2026 with Mr. Campiciano filed as Exhibit 10.1

The filing

CompanyPropanc Biopharma, Inc. (PPCB)
Form8-K, current report
Filed with the SECJul 14, 2026, 4:01 PM ET
Accession number0001493152-26-033173

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 14, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.